Company to Highlight Clinical Progress for ProLectin-M and Discuss the Broader Potential of Its Galectin-Targeted Therapeutics Platform
BOSTON, Dec. 12, 2022 (GLOBE NEWSWIRE) — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing investigational carbohydrate-based therapeutics for viral diseases, hypoxia, and degenerative disorders, today announced that Chief Marketing Officer Michael Sheikh will present the Company's latest clinical trial results and corporate update during the Emerging Growth Conference on Wednesday, December 14, 2022, at 1:45 p.m. EST.
During the presentation, Bioxytran will discuss recent clinical findings for its lead investigational antiviral candidate, ProLectin-M, along with the scientific rationale behind the Company's galectin-targeted platform and its broader development strategy across viral diseases and other therapeutic areas.
The presentation will also provide investors with insight into Bioxytran's clinical development roadmap, ongoing research initiatives, and the potential applications of its carbohydrate-based drug design platform.
Bioxytran's lead investigational therapy, ProLectin-M, is designed to target Galectin-3, a carbohydrate-binding protein involved in viral attachment, immune signaling, inflammation, and fibrosis.
Unlike conventional antiviral therapies that primarily inhibit viral replication after infection has occurred, ProLectin-M is being investigated as a galectin antagonist that may interfere with viral entry into host cells. This mechanism represents a differentiated scientific approach and forms the foundation of Bioxytran's broader Glycovirology platform.
Beyond COVID-19, the Company continues to explore how galectin-targeted therapeutics may support future research across multiple viral and inflammatory diseases.
Event: Emerging Growth Conference
Date: Wednesday, December 14, 2022
Time: 1:45 p.m. – 2:15 p.m. EST
Registration: [Conference Registration Link]
Investors are encouraged to register in advance to attend the live webcast and receive conference updates. An archived replay will also be made available through EmergingGrowth.com following the event.
The Emerging Growth Conference provides public companies with a platform to communicate significant corporate developments, scientific advancements, and business strategies directly to individual and institutional investors.
The conference features companies across a range of high-growth industries and offers investors an opportunity to engage with executive leadership through live webcast presentations.
Bioxytran, Inc. is a clinical-stage biotechnology company developing investigational carbohydrate-based therapeutics designed to address significant unmet medical needs in virology, hypoxia, inflammation, fibrosis, and degenerative disease.
The Company's proprietary platform combines carbohydrate drug design, Glycovirology, and galectin-targeted science to investigate new approaches for preventing viral entry, modulating immune responses, and improving oxygen delivery during tissue injury.
Bioxytran's lead investigational candidate, ProLectin-M, is being studied as a galectin antagonist designed to interfere with viral entry into host cells. The Company is also advancing additional investigational programs focused on hypoxia, pulmonary fibrosis, stroke, and other diseases where oxygen deprivation and inflammatory signaling play important roles.
Additional information is available at www.bioxytraninc.com.
This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, but are not limited to, statements regarding the Company's investigational therapies, anticipated clinical development activities, conference presentations, future research programs, and potential therapeutic applications of its platform technologies.
Forward-looking statements are based on current expectations and are subject to risks and uncertainties that may cause actual results to differ materially. These risks include clinical development outcomes, regulatory decisions, research results, financing requirements, market conditions, and other factors described in Bioxytran's filings with the U.S. Securities and Exchange Commission. Bioxytran undertakes no obligation to update any forward-looking statements except as required by applicable law.
For more information, please visit:
Visit the original announcement:
https://www.nasdaq.com/press-release/bioxytran-interview-at-the-emerging-growth-conference-2022-12-12
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
